Apotex Acquires CanPrev

SK Capital Partners Acquires Apotex Pharmaceutical Holdings

April 3, 2023

Pharmaceuticals

An affiliate of funds advised by SK Capital Partners has completed the acquisition of Apotex Pharmaceutical Holdings Inc. SK Capital appointed Allan Oberman as President and CEO as it looks to transform Apotex into a Canadian-based global health company; Apotex employs nearly 8,000 people and sells affordable medicines in over 100 countries.

Apotex Acquires Searchlight Pharma

April 2, 2024

Pharmaceuticals

Apotex Inc. has completed the acquisition of Montreal-based Searchlight Pharma Inc., integrating Searchlight as Apotex's Specialty Pharma Division to expand its branded and specialty pharmaceutical capabilities. The deal adds Searchlight's portfolio of more than 60 products across women's health, dermatology, allergy, pain management and hospital specialty markets, and strengthens Apotex's commercial footprint in Quebec and across the Americas.

Abenex and Arkéa Capital Acquire Majority Stake in Prévost Laboratory Concept

May 11, 2020

Manufacturing

Abenex (via Abenex Croissance) has acquired a majority stake in Prévost Laboratory Concept, a Nouvoitou, France-based contract laboratory that formulates, produces and packages cosmetics, food supplements and animal care products. The deal is supported by Arkéa Capital and founder Véronique Prévost (who remains chairman); the company employs ~30 people and generates about €8 million in revenue and will pursue accelerated organic and international growth.

JBT Corporation Acquires Prevenio

July 9, 2021

Food & Beverage

JBT Corporation agreed to acquire Prevenio (fka CMS Technology) in an all-cash transaction for $170 million. The acquisition brings Prevenio’s food-safety technology and recurring revenue streams into JBT’s FoodTech portfolio and represents an exit for investor WP Global Partners.

Isracann Biosciences to Acquire Praesidio Health

February 23, 2022

Biotechnology

Isracann Biosciences Inc. entered into a binding letter of intent to acquire Canadian medical research company Praesidio Health Inc. under a stock transaction valued at approximately CAD 4.0 million. Praesidio develops and validates evidence-based natural health medicines (including formulations with cannabinoids and/or psilocybin) for conditions such as urological disorders, anxiety/stress, immune support and sleep.

Eli Lilly Acquires Prevail Therapeutics

December 15, 2020

Biotechnology

Eli Lilly agreed to acquire Prevail Therapeutics for $22.50 per share in cash (approximately $880 million) plus a non-tradable contingent value right (CVR) worth up to $4.00 per share (up to ~$160 million), for total consideration of up to ~$1.04 billion. The deal establishes a gene therapy program at Lilly anchored by Prevail’s AAV9-based neuroscience pipeline; the transaction was structured as a tender offer with expected close in Q1 2021 subject to customary conditions.